Cargando…
Informing Global Cost-Effectiveness Thresholds Using Country Investment Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018
OBJECTIVES: Cost-effectiveness analysis can guide decision making about health interventions, but the appropriate cost-effectiveness threshold to use is unclear in most countries. The World Health Organization (WHO) recommends vaccinating girls 9 to 14 years against human papillomavirus (HPV), but o...
Autor principal: | Jit, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813214/ https://www.ncbi.nlm.nih.gov/pubmed/33431154 http://dx.doi.org/10.1016/j.jval.2020.07.012 |
Ejemplares similares
-
What We Do Not Know About the Costs of Immunization Programs in Low- and Middle-Income Countries
por: Portnoy, Allison, et al.
Publicado: (2021) -
Costs of Immunization Programs for 10 Vaccines in 94 Low- and Middle-Income Countries From 2011 to 2030
por: Sim, So Yoon, et al.
Publicado: (2021) -
How to Prevent Vaccines Falling Victim to Their Own Success: Intertemporal Dependency of Incidence Levels on Indirect Effects in Economic Reevaluations
por: Sandmann, Frank, et al.
Publicado: (2021) -
Evaluating Vaccination Programs That Prevent Diseases With Potentially Catastrophic Health Outcomes: How Can We Capture the Value of Risk Reduction?
por: Mauskopf, Josephine, et al.
Publicado: (2021) -
The global burden of bacterial and viral zoonotic infections
por: Christou, L.
Publicado: (2011)